• Lisa J. StatesEmail author
  • Klaus Mohnike
Part of the Contemporary Endocrinology book series (COE)


One of the main goals in the evaluation of congenital hyperinsulinism is to distinguish medically treatable disease from disease requiring surgical management. Over the past 20 years, it has become clear that some patients with severe disease that is unresponsive to medical therapy may benefit from pancreatectomy. One of the big challenges has been distinguishing between two histopathologic forms of HI, diffuse disease, which is not curable, and focal disease, which can be cured with limited pancreatic resection. Diagnostic evaluation with the 18-F-L-3,4-dihydroxyphenylalanine [18F]-DOPA PET scan has been shown to have moderate-good sensitivity for diagnosis of a focal lesion but almost 100% accuracy in localizing a detected lesion. The finding of a focal lesion can change surgical approach, decrease surgical morbidity, and lead to a cure of this devastating disease.


18F-DOPA PET/CT Hyperinsulinemic hypoglycemia 


  1. 1.
    Mohnike K, et al. [18F]-DOPA positron emission tomography for preoperative localization in congenital hyperinsulinism. Horm Res. 2008;70:65–72.CrossRefGoogle Scholar
  2. 2.
    De Leon DD, Stanley CA. Congenital hypoglycemia disorders: new aspects of etiology, diagnosis, treatment and outcomes. Highlights of the proceedings of the congenital hypoglycemia disorders symposium, Philadelphia April 2016. Pediatr Diabetes. 2016; Scholar
  3. 3.
    Yorifuji T, et al. Clinical practice guidelines for congenital hyperinsulinism. Clin Endocrinol. 2017;26(3):127–52.Google Scholar
  4. 4.
    Ribeiro MJ, De Lonlay P, Delzescaux T, Boddaert N, Jaubert F, Bourgeois S, Dollé F, Nihoul-Fékété C, Syrota A, Brunelle F. Characterization of hyperinsulinism in infancy assessed with PET and 18F-fluoro-LDOPA. J Nucl Med. 2005;46(4):560–6.Google Scholar
  5. 5.
    Otonkoski T, Nänto-Salonen K, Seppanen M, Veijola R, Huopio H, Hussain K, Tapanainen P, Eskola O, Parkkola R, Ekstrom K, Guiot Y, Rahier J, Laakso M, Rintala R, Nuutila P, Minn H. Noninvasive diagnosis of focal hyperinsulinism of infancy with [18F]-DOPA positron emission tomography. Diabetes. 2006;55(1):13–8.CrossRefGoogle Scholar
  6. 6.
    Ribeiro MJ, et al. The added value of [18F]fluoro-L-DOPA PET in the diagnosis of hyperinsulinism of infancy: a retrospective study involving 49 children. Eur J Nucl Med Mol Imaging. 2007;34(12):2120–8.CrossRefGoogle Scholar
  7. 7.
    Hardy OT, et al. Accuracy of [18F]fluorodopa positron emission tomography for diagnosing and localizing focal congenital hyperinsulinism. J Clin Endocrinol Metab. 2007;92(12):47.CrossRefGoogle Scholar
  8. 8.
    Barthlen W, et al. Evaluation of [18F]fluoro-L-DOPA positron emission tomography-computed tomography for surgery in focal congenital hyperinsulinism. J Clin Endocrinol Metab. 2008;93(3):869–75. 06–11.CrossRefGoogle Scholar
  9. 9.
    Capito C, et al. Value of 18F-fluoro-L-dopa PET in the preoperative localization of focal lesions in congenital hyperinsulinism. Radiology. 2009;253(1):216–22.CrossRefGoogle Scholar
  10. 10.
    Masue M, et al. Diagnostic accuracy of [18F]-fluoro-L-dihydroxyphenylalanine positron emission tomography scan for persistent congenital hyperinsulinism in Japan. Clin Endocrinol. 2011;75(3):342–6.CrossRefGoogle Scholar
  11. 11.
    Zani A, et al. The predictive value of preoperative fluorine-18-L-3,4-dihydroxyphenylalanine positron emission tomography-computed tomography scans in children with congenital hyperinsulinism of infancy. J Pediatr Surg. 2011;46(1):204–8.CrossRefGoogle Scholar
  12. 12.
    Laje P, et al. Accuracy of PET/CT scan in the diagnosis of the focal form of congenital hyperinsulinism. J Pediatr Surg. 2013;48(2):388–93.CrossRefGoogle Scholar
  13. 13.
    Meintjes M, et al. 18F-DOPA PET and enhanced CT imaging for congenital hyperinsulinism: initial UK experience from a technologist’s perspective. Nucl Med Commun. 2013;34(6):601–8.CrossRefGoogle Scholar
  14. 14.
    Kuhnen P, et al. Occurrence of giant focal forms of congenital hyperinsulinism with incorrect visualization by (18) F DOPA-PET/CT scanning. Clin Endocrinol. 2014;81(6):847–54.CrossRefGoogle Scholar
  15. 15.
    Chevalme Y, et al. FDOPA-(18F): a PET radiopharmaceutical recently registered for diagnostic use in countries of the European Union. Braz Arch Biol Technol. 2007;50:77–90.CrossRefGoogle Scholar
  16. 16.
    Lindstrom P, Sehlin J. Aromatic amino acids and pancreatic islet function: a comparison of L-tryptophan and L-5-hydroxytryptophan. Mol Cell Endocrinol. 1986;48:121–6.CrossRefGoogle Scholar
  17. 17.
    de Lonlay P, et al. Congenital hyperinsulinism: pancreatic [18F]fluoro-L-dihydroxyphenylalanine (DOPA) positron emission tomography and immunohistochemistry study of DOPA decarboxylase and insulin secretion. J Clin Endocrinol Metab. 2006;91(3):933–40.CrossRefGoogle Scholar
  18. 18.
    Sempoux C, Guiot Y, Dahan K, Moulin P, Stevens M, Lambot V, de Lonlay P, Fournet J-C, Junien C, Jaubert F, Nihoul-Fekete C, Saudubray J-M, Rahier J. The focal form of persistent hyperinsulinemic hypoglycemia of infancy: morphological and molecular studies show structural and functional differences with insulinoma. Diabetes. 2003;52(3):784–94.CrossRefGoogle Scholar
  19. 19.
    Hussain K, Seppanen M, Nanto-Salonen K, Adzick NS, Stanley CA, Minn H. J Clin Endocrinol Metab. 2006;91:2839–42.CrossRefGoogle Scholar
  20. 20.
    Peranteau WH, Batharr SM, Pawel B, Hardy O, Alavi A, Stanley CA, Adzick NA. Multiple ectopic lesions of focal islet adenomatosis identified by positron emission tomography scan in an infant with congenital hyperinsulinism. J Ped Surg 2007. 2007;42(1):188–92.Google Scholar
  21. 21.
    Mohnike K, et al. Proposal for a standardized protocol for 18F-DOPA-PET (PET/CT) in congenital hyperinsulinism. Horm Res. 2006;66:40–2.PubMedGoogle Scholar
  22. 22.
    Moerlein S, et al. Validation of a nucleophilic synthesis platform for a clinical application of [18] Fluordopa. J Nucl Med. 2017;58(suppl 1):255.Google Scholar
  23. 23. SNMMI PET center of excellence and the center for molecular imaging innovation & translation. May 2013:1–8. 22.Google Scholar
  24. 24.
    Arnoux JB, de Lonlay P, Ribeiro MJ, Hussain K, Blankenstein O, Mohnike K, Valayannopoulos V, Robert JJ, Rahier J, Sempoux C, Bellanné C, Verkarre V, Aigrain Y, Jaubert F, Brunelle F, Nihoul-Fékété C. Congenital hyperinsulinism. Early Hum Dev. 2010;86(5):287–94.CrossRefGoogle Scholar
  25. 25.
    Garg PK, Lokitz SJ, Truong L, Putegnat B, Reynolds C, Rodriguez L, et al. Pancreatic uptake and radiation dosimetry of 6-[18F]fluoro-L-DOPA from PET imaging studies in infants with congenital hyperinsulinism. PLoS One. 2017;12(11):e0186340. Scholar
  26. 26.
    Harvey J, Firnau G, Garnett ES. Estimation of radiation dose in man due to 6-[18F]Fluoro-L-Dopa. J Nucl Med. 1985;26:931–5.PubMedGoogle Scholar
  27. 27.
    Dhawan VB, Belakhlef A, Robeson A, Ishikawa W, Margouleff T, Takikawa C, Chaly S, Kazumata T, Margouleff K, Eidelberg D. Bladder wall radiation dose in humans from fluorine-18-FDOPA. J Nucl Med. 1996;37:1850–2. 26.Google Scholar
  28. 28.
    National Research Council. Health risks from exposure to low levels of ionizing radiation: BEIR VII phase 2. Washington, DC: The National Academies Press; 2006. Scholar
  29. 29.
    von Rohden L, Mohnike K, Mau H, Eberhard T, Mohnike W, Blankenstein O, Empting S, Koch M, Fuchtner F, Barthlen W. Intraoperative sonography: a technique for localizing focal forms of congenital hyperinsulinism in the pancreas. Ultraschall Med. 2011;32(1):74–80.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.Department of RadiologyThe Children’s Hospital of PhiladelphiaPhiladelphiaUSA
  2. 2.Otto-von-Guericke Universität, UniversitätskinderklinikMagdeburgGermany

Personalised recommendations